NASDAQ:PRE Prenetics Global Q1 2025 Earnings Report $19.36 +1.35 (+7.46%) As of 03:06 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Prenetics Global EPS ResultsActual EPS-$0.80Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/APrenetics Global Revenue ResultsActual Revenue$17.31 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APrenetics Global Announcement DetailsQuarterQ1 2025Date6/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsPrenetics Global's Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 13, 2026 at 8:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesEarnings HistoryCompany Profile Prenetics Global Earnings HeadlinesWall Street Zen Downgrades Prenetics Global (NASDAQ:PRE) to SellJuly 25, 2026 | americanbankingnews.comPrenetics Global: Path To Profitability On Course With Financing DealJuly 24, 2026 | seekingalpha.comThe dollar reset no one told you aboutPorter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.July 30 at 1:00 AM | Porter & Company (Ad)Sidoti Estimates Prenetics Global's Q3 Earnings (NASDAQ:PRE)July 19, 2026 | americanbankingnews.comPrenetics’ IM8 Secures $1 Billion Non-Dilutive Financing as Revenue Outlook RisesJuly 17, 2026 | theglobeandmail.comPRE Continues to Exceed Expectations and Receive Preferential FinancingJuly 17, 2026 | msn.comSee More Prenetics Global Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Prenetics Global? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prenetics Global and other key companies, straight to your email. Email Address About Prenetics GlobalPrenetics Global (NASDAQ:PRE) (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting. Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America. Its consumer brand, CircleDNA, offers a direct-to-consumer genetic testing kit that reports on wellness traits, nutrition, fitness and inherited disease risks. On the corporate side, the company partners with healthcare providers, sports organizations and governments to deploy large-scale testing programs and personalized health initiatives. Prenetics also supports telehealth services, enabling remote consultations based on genetic and diagnostic results. Founded in 2014 and headquartered in Hong Kong, Prenetics was established by CEO Danny Yeung, a tech entrepreneur with a background in fintech and digital platforms. Under his leadership, the company has expanded through strategic partnerships and investments in laboratory automation and data analytics. Prenetics completed a public listing on the Nasdaq in 2022, positioning itself to accelerate global market expansion and further develop its precision health offerings.View Prenetics Global ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Microsoft Just Flipped the AI Spending Narrative OvernightQualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?Can Starbucks Keep This Turnaround Going? The Latest Results Say YesTesla: After a Rough Quarter, 2 Very Different Futures Come Into FocusMeta’s Earnings Show Why Wall Street Is Losing Patience With AI SpendingWhy NXP Semiconductors Could Be the AI Stock Everyone Is MissingPalantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Upcoming Earnings Linde (7/31/2026)Keysight Technologies (7/31/2026)Colgate-Palmolive (7/31/2026)Chevron (7/31/2026)Enbridge (7/31/2026)ExxonMobil (7/31/2026)NatWest Group (7/31/2026)Sumitomo Mitsui Financial Group (7/31/2026)Eaton (7/31/2026)AbbVie (7/31/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
